Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastricor gastroesophageal junction carcinoma-Reference-Cited by-同舟云学术

Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastricor gastroesophageal junction carcinoma

Published:2004-05 Issue:5 Volume:15 Page:765-769
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mitry E.,Taïeb J.,Artru P.,Boige V.,Vaillant J.-N.,Clavero-Fabri M.-C.,Ducreux M.,Rougier P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/15/5/765/463935/mdh182.pdf

Reference18 articles.

1. Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer;Murad;Cancer,1993

2. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer;Pyrhonen;Br J Cancer,1995

3. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer;Glimelius;Ann Oncol,1997

4. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer;Webb;J Clin Oncol,1997

5. A phase III randomized study of 5‐fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer;Kim;Cancer,1993

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR);Digestive and Liver Disease;2023-12

2. Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort;Cancer Medicine;2022-11-16

3. Nouvelles AMMs au niveau européen : nivolumab – carcinome épidermoïde de l’œsophage non opérable en deuxième ligne thérapeutique;Bulletin du Cancer;2021-03

4. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study;Digestive and Liver Disease;2020-03

5. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma;Indian Journal of Cancer;2019